In recent weeks, the Trump Administration released a long-awaited on the Alternative Dispute Resolution (ADR) process in the 340B Drug Discount Program (340B Program).

As part of the Department of Health and Human Services’ (HHS’) “Regulatory Sprint to Coordinated Care,” the Centers for Medicare & Medicaid Services (CMS) and the HHS Office of the Inspector General (OIG) both released final regulations on Friday, November 20, 2020.

HTCs often inquire with the Hemophilia Alliance regarding what is an appropriate “indirect cost rate.”

Under the auspices of 340B Program compliance, manufacturers recently requested extensive data from covered entities related to drugs dispensed through contract pharmacies.

Under the auspices of 340B Program compliance, manufacturers recently requested extensive data from covered entities related to drugs dispensed through contract pharmacies.

In recent weeks, three drug manufacturers have taken unprecedented actions that threaten covered entity participation in the 340B Discount Drug Pricing Program (340B Program).

Helping Patients Impacted by COVID-19 through Chapters